Prevention strategies for CV health
- Alexandros Tselepis, Greece
- Zeljko Reiner, Croatia
Precision nutrition and CVD management
Jogchum Plat, Maastricht, The Netherlands
Behaviour change in CVD prevention
Heike Englert, Münster, Germany
Can technology improve adherence to lifestyle?
Gil Blander, Boston, USA
NLA-EAS joint session: Dyslipidemia Treatment in Light of the New Guidelines
- Lale Tokgözoglu, Turkey
- Antonio Gotto, USA
Targets and goals: The EAS way
Chris Packard, Glasgow, UK
Targets and goals: The NLA way
Carl E. Orringer, Miami, USA
Therapeutic Approaches: The EAS way
Alberico L. Catapano, Milan, Italy
Therapeutic Approaches: The NLA way
Christie Ballantyne, Houston, USA
Novel approaches to lipid lowering management
- Alberico L. Catapano, Italy
- Marja-Riita Taskinen, Finland
What is the landscape on lipid management today?
Lale Tokgözoglu, Ankara, Turkey
When do we need add on therapies to statin?
Ulrich Laufs, Leipzig, Germany
What do we know so far about bempedoic acid?
Kausik Ray, London, UK
Targeting lower LDL-C: When and how?
- Lale Tokgözoglu, Turkey
- David Wood, UK
Are the new EAS/ESC lipoid goals reachable in clinical practice?
François Mach, Geneva, Switzerland
Risk stratification in very high risk patients is it of value?
Kosh Ray, London, UK
An update on the results of ODYSSEY outcomes
Gabriel Steg, Paris, France
The role of TG-rich lipoproteins in atherosclerosis
- Jan Boren, Sweden
- Philippe Moulin, France
TG-rich lipoproteins as a risk factor
Ruth Frikke-Schmidt, Copenhagen, Denmark
The value of omega 3: from biology to clinical practice
Alberto Zambon, Padova, Italy
Position of omega 3 in Guidelines (as second choice after statins)
Christie Ballantyne, Houston, USA
Case: Diabetic patient with MI - how to manage?
Dirk Mueller, Köln, Germany
Implementing guidelines: a patient-centered approach for daily practice
- Paolo Parini, Sweden
- Marat Ezhov, Russia
Why and in whom is combination needed?
Luis Masana, Barcelona, Spain
Difficult cases to reach goal: FH
Meral Kayikcioglu, Izmir, Turkey
Difficult cases to reach goal: Recurrent event on statin
Michel Farnier, Dijon, France
Can combination aid adherence? (fixed dose, intolerance)
Michal Vrablik, Prague, Czech Republic
Translating science into guidance on the prevention of cardiovascular disease
Guy de Backer, Ghent, Belgium
New ways to modulate TG metabolic pathways
- Arnold von Eckardstein, Switzerland
- Christoph Binder, Austria
The Angiopoietin-like proteins, controlling lipoprotein metabolism
Marcello Arca, Rome, Italy
ANGPTL 3 what we have learned from genetics?
Sander Kersten, The Netherlands
ANGPTL 3 Inhibition: recent clinical trials
Daniel Gaudet, Montreal, Canada
Future directions – Round Table
